Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS

https://doi.org/10.1182/bloodadvances.2022009493 17th July 2023

Article highlights & insights

Allogeneic stem-cell transplant allows for the delivery of curative graft-versus-leukemia (GVL) in patients with acute myeloid leukemia/myelodysplasia (AML/MDS). Surveillance of T-cell chimerism, measurable residual disease (MRD) and blast HLA-DR expression may inform whether GVL effectiveness is reduced.

Loke et al report here the prognostic impact of these biomarkers in patients allografted for AML/MDS. One hundred eighty-seven patients from FIGARO, a randomised trial of reduced-intensity conditioning regimens in AML/MDS, were alive and relapse-free at the first MRD time-point and provided monitoring samples for flow cytometric MRD and T-cell chimerism, requested to month+12. Twenty-nine (15.5%) patients had at least 1 MRD-positive result posttransplant. MRD-positivity was associated with reduced overall survival (OS) (hazard ratio [HR], 2.18; P = .0028) as a time-varying Cox variable and remained significant irrespective of pretransplant MRD status in multivariate analyses (P < .001).

Ninety-four patients had sequential MRD with T-cell chimerism results at months+3/+6. Patients with full donor T-cell chimerism (FDTC) had an improved OS as compared with patients with mixed donor T-cell chimerism (MDTC) (adjusted HR=0.4; P = .0019). In patients with MDTC (month+3 or +6), MRD-positivity was associated with a decreased 2-year OS (34.3%) vs MRD-negativity (71.4%) (P = .001). In contrast, in the group with FDTC, MRD was infrequent and did not affect the outcome. Among patients with posttransplant MRD-positivity, decreased HLA-DR expression on blasts significantly reduced OS, supporting this as a mechanism for GVL escape.

In conclusion, posttransplant MRD is an important predictor of the outcome in patients allografted for AML/MDS and is most informative when combined with T-cell chimerism results, underlining the importance of a GVL effect in AML/MDS.

Four individuals pose together in a laboratory. They're wearing lab coats each with a Cancer Research UK logo.
An immunofluorescence microscopy image of kidney tissue showing different tissue structures stained in red, blue, and green The blue colour (DAPI) is widespread, indicating the location of cell nuclei throughout the sample. The green colour (LTL) highlights specific regions, indicating the presence of proximal tubule cells. The red colour (NPHS1) is also distinct in certain areas, showing the presence of podocytes in the glomeruli. The overlapping colours in some regions suggest the complex structure and the close association of these different cell types within the kidney.

Latest from CRUK MI

New major support for our lung cancer prevention research

ScottishPower has committed £690,000 to co-fund our Cancer Origins research group with the University of Manchester, enabling investigations into what causes lung cancer to emerge and how we can prevent it.

New publication: Bacteria inside kidney tumors associate with myeloid inflammation and disease progression – A TRACERx Renal study

Research explores the role of intratumour bacteria in disease progression

Read our latest Scientific Report

The latest Scientific Report highlights an incredible year of growth for the Institute and many research successes. We welcomed a new Director, Samra Turajlić to the Institute, and saw the establishment of three new independent research groups.

New major support for our lung cancer prevention research
New publication: Bacteria inside kidney tumors associate with myeloid inflammation and disease progression – A TRACERx Renal study
Read our latest Scientific Report